These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 1573974)
1. Apparent pA2 value of naltrexone is not changed in rats following continuous exposure to morphine or naloxone. Paronis CA; Holtzman SG Life Sci; 1992; 50(19):1407-16. PubMed ID: 1573974 [TBL] [Abstract][Full Text] [Related]
2. Increased analgesic potency of mu agonists after continuous naloxone infusion in rats. Paronis CA; Holtzman SG J Pharmacol Exp Ther; 1991 Nov; 259(2):582-9. PubMed ID: 1658305 [TBL] [Abstract][Full Text] [Related]
3. Development of tolerance to the analgesic activity of mu agonists after continuous infusion of morphine, meperidine or fentanyl in rats. Paronis CA; Holtzman SG J Pharmacol Exp Ther; 1992 Jul; 262(1):1-9. PubMed ID: 1625189 [TBL] [Abstract][Full Text] [Related]
4. Apparent affinity of opioid antagonists in morphine-treated rhesus monkeys discriminating between saline and naltrexone. France CP; de Costa BR; Jacobson AE; Rice KC; Woods JH J Pharmacol Exp Ther; 1990 Feb; 252(2):600-4. PubMed ID: 2156055 [TBL] [Abstract][Full Text] [Related]
5. In vivo apparent pA2 analysis for naltrexone antagonism of discriminative stimulus and analgesic effects of opiate agonists in rats. Walker EA; Makhay MM; House JD; Young AM J Pharmacol Exp Ther; 1994 Nov; 271(2):959-68. PubMed ID: 7965818 [TBL] [Abstract][Full Text] [Related]
6. Possible involvement of mu1-opioid receptors in the fentanyl- or morphine-induced antinociception at supraspinal and spinal sites. Narita M; Imai S; Itou Y; Yajima Y; Suzuki T Life Sci; 2002 Apr; 70(20):2341-54. PubMed ID: 12150199 [TBL] [Abstract][Full Text] [Related]
7. Acute opioid pretreatment potentiates naltrexone-induced drinking suppression in water-deprived rats. White DA; Holtzman SG J Pharmacol Exp Ther; 2001 Jul; 298(1):156-64. PubMed ID: 11408537 [TBL] [Abstract][Full Text] [Related]
8. Measuring naloxone antagonism of discriminative opioid stimulus. Krimmer EC; Barry H Fed Proc; 1982 May; 41(7):2319-22. PubMed ID: 7042395 [TBL] [Abstract][Full Text] [Related]
9. Relative involvement of mu, kappa and delta receptor mechanisms in opiate-mediated antinociception in mice. Ward SJ; Takemori AE J Pharmacol Exp Ther; 1983 Mar; 224(3):525-30. PubMed ID: 6131119 [TBL] [Abstract][Full Text] [Related]
10. The potentiating effects of restraint stress and continuous naloxone infusion on the analgesic potency or morphine are additive. Levesque D; Holtzman SG Brain Res; 1993 Jul; 617(1):176-80. PubMed ID: 8374741 [TBL] [Abstract][Full Text] [Related]
11. Assessment of relative intrinsic activity of mu-opioid analgesics in vivo by using beta-funaltrexamine. Adams JU; Paronis CA; Holtzman SG J Pharmacol Exp Ther; 1990 Dec; 255(3):1027-32. PubMed ID: 2175793 [TBL] [Abstract][Full Text] [Related]
12. Increased analgesic potency of morphine and increased brain opioid binding sites in the rat following chronic naltrexone treatment. Yoburn BC; Goodman RR; Cohen AH; Pasternak GW; Inturrisi CE Life Sci; 1985 Jun; 36(24):2325-32. PubMed ID: 2989632 [TBL] [Abstract][Full Text] [Related]